Some joint soreness can wait, and some needs care now

Mild soreness often allows a little time and gentler movement

When the joint still works and the soreness is mild, do less of the activity that caused it. Keep some gentle motion if that doesn't bring sharp pain. Rest needn't mean sitting still all day. A cane or brace can make the joint steadier. Take medicine only if your own doctor says it won't clash with your health needs or prescriptions.

Don't ignore the joint over the next few days. Swelling ought to ease, movement may get easier, and sleep may improve. If the ache keeps returning or still limits your day, arrange an exam. You can ask for help before the soreness becomes unbearable.

Soreness that stays needs a closer look.

Heat, fever, lost strength, or a major injury needs prompt care

Get urgent care when a badly swollen joint feels hot and you have fever or sudden illness. Redness, drainage, spreading warmth, or fast-rising pain after a joint procedure also needs prompt help. New numbness or weakness can't wait. Neither can the front of your foot dragging as you walk, or loss of bladder or bowel control. Calf pain with swelling after sitting still may mean a blood clot.

After urgent trouble is ruled out, QC Kinetix can discuss regenerative treatment options such as platelet-rich plasma (PRP), a shot made by separating your blood and keeping more clotting cells. The clinic's medical staff place that concentrated part near the sore area. This visit can't replace emergency care. Tell them about blood thinners, bleeding trouble, infection, and all prescriptions. Don't quit a blood thinner without your doctor's help.

Safety comes first.

Sources

1. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

3. A Bayesian network meta-analysis of nine studies (six RCTs, 1055 patients) found leukocyte-POOR PRP produced significantly better WOMAC scores than hyaluronic acid (mean difference -21.14; 95% CI -39.63 to -2.65) and than placebo (-17.84; 95% CI -34.95 to -0.73), while leukocyte-RICH PRP showed no such significant difference versus placebo. PRP of either type caused more local adverse reactions than hyaluronic acid (OR 5.63; 95% CI 1.38-22.90), almost always local swelling and pain, with no difference in safety between the two PRP types.

   Riboh JC, Saltzman BM, Yanke AB, et al. — Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis. American Journal of Sports Medicine, 2016. DOI: 10.1177/0363546515580787.

4. In a double-blind, placebo-controlled trial of 54 patients with chronic midportion Achilles tendinopathy, all doing eccentric exercises, VISA-A scores improved 21.7 points with PRP and 20.5 points with saline over 24 weeks - an adjusted between-group difference of -0.9 (95% CI -12.4 to 10.6), excluding the predefined relevant difference of 12 points. PRP added nothing to eccentric loading.

   de Vos RJ, Weir A, van Schie HT, et al. — Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA, 2010. DOI: 10.1001/jama.2009.1986.

5. A multicentre, double-blinded, placebo-controlled trial randomised 100 patients with ankle (tibiotalar) osteoarthritis to two ultrasound-guided intra-articular injections of PRP or placebo. Symptom scores improved by 10 points with PRP and 11 points with placebo, an adjusted between-group difference over 26 weeks of -1 (95% CI -6 to 3; P=.56). The authors concluded the results do not support the use of PRP injections for ankle osteoarthritis.

   Paget LDA, Reurink G, de Vos RJ, et al. — Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.16602.

6. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.